We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$9.59B
1-Year Est. Return
113.36%
This Fund
S&P 500
This Quarter
Est. Return
-2.77%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$4.85B
AUM Growth
+$375M
(+8.4%)
Cap. Flow
-$1.36B
Cap. Flow
% of AUM
-27.99%
Top 10 Holdings %
Top 10 Hldgs %
37.89%
Holding
140
New
14
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$50.2M |
| 2 |
Gilead Sciences
GILD
|
+$48.7M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$32.8M |
| 4 |
MRUS
Merus
MRUS
|
+$32.3M |
| 5 |
Glaukos
GKOS
|
+$31.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kura Oncology
KURA
|
+$25.7M |
| 2 |
Organogenesis Holdings
ORGO
|
+$24.7M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$22.2M |
| 4 |
GoodRx Holdings
GDRX
|
+$18.9M |
| 5 |
Nuvation Bio
NUVB
|
+$18.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.03% |
| 2 | Miscellaneous | 46.58% |
| 3 | Financials | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NUVL
1
DELISTED
Nuvalent
NUVL
| $262M | 5.41% |
19,341,024
| – | – |
|
2
Viatris
VTRS
$19.4B
| $216M | 4.46% |
20,673,700
| – | – |
|
3
AdaptHealth
AHCO
$866M
| $201M | 4.15% |
11,150,797
-499,275
| -4% | -$8.11M |
|
|
4
Neurocrine Biosciences
NBIX
$15.8B
| $196M | 4.05% |
2,012,714
+354,914
| +21% | +$32.8M |
|
5
CALL
Biogen
BIIB
$32.6B
| $102M | 2.1% |
+500,000
| New | +$102M |
|
|
SILK
6
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $97.4M | 2.01% |
2,676,891
+523,179
| +24% | +$19M |
|
|
7
Gilead Sciences
GILD
$187B
| $96M | 1.98% |
1,552,639
+787,150
| +103% | +$48.7M |
|
|
DCPH
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $82.2M | 1.7% |
6,250,964
+670,508
| +12% | +$7.4M |
|
|
IMGN
9
DELISTED
Immunogen Inc
IMGN
| $67.6M | 1.39% |
15,020,490
+11,549,815
| +333% | +$50.2M |
|
10
Mirum Pharmaceuticals
MIRM
$6.15B
| $63.1M | 1.3% |
3,244,434
-38,478
| -1% | -$908K |
|
|
DAWN
11
DELISTED
Day One Biopharmaceuticals
DAWN
| $62.9M | 1.3% |
3,512,123
+1,425,674
| +68% | +$14.7M |
|
|
CMAX
12
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $57.6M | 1.19% |
528,703
| – | – |
|
13
Cogent Biosciences
COGT
$6.03B
| $53M | 1.09% |
5,876,805
+4,275,805
| +267% | +$29.2M |
|
14
Pulmonx
LUNG
$94.9M
| $51M | 1.05% |
3,465,901
-229,440
| -6% | -$4.73M |
|
|
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $50.2M | 1.03% |
5,214,000
+322,004
| +7% | +$4.04M |
|
16
Centene
CNC
$33.1B
| $49M | 1.01% |
578,800
+25,000
| +5% | +$2.08M |
|
|
17
Kura Oncology
KURA
$1.18B
| $48.2M | 0.99% |
2,627,000
-1,789,361
| -41% | -$25.7M |
|
|
18
Glaukos
GKOS
$10.5B
| $47.2M | 0.97% |
1,039,514
+670,000
| +181% | +$31.8M |
|
19
Molina Healthcare
MOH
$10.5B
| $46.7M | 0.96% |
167,000
+32,011
| +24% | +$9.67M |
|
20
Cytokinetics
CYTK
$10.1B
| $45.6M | 0.94% |
1,160,315
+207,612
| +22% | +$8.36M |
|
|
MRUS
21
DELISTED
Merus
MRUS
| $45M | 0.93% |
1,985,924
+1,548,924
| +354% | +$32.3M |
|
22
Evolus
EOLS
$614M
| $42.1M | 0.87% |
3,632,751
+2,403,517
| +196% | +$28.4M |
|
23
Brookdale Senior Living
BKD
$2.81B
| $39M | 0.8% |
8,592,461
+3,213,461
| +60% | +$19M |
|
|
AERI
24
DELISTED
Aerie Pharmaceuticals
AERI
| $35.2M | 0.73% |
4,695,020
| – | – |
|
25
Edgewise Therapeutics
EWTX
$4.68B
| $31.3M | 0.65% |
3,933,137
| – | – |
|
Similar funds
OAM
BTI
WAM
MSE
VF
GGHC
A
Deerfield Management's Q2 2022 Portfolio in Review
As of Q2 2022, Deerfield Management held 140 positions worth $4.85B, up 8.4% from $4.47B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Deerfield Management withdrew a net $1.36B in Q2 2022, closing 14 positions and reducing 12 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $22.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 55% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Deerfield Management opened a new position in HilleVax worth $28.6M.
- Deerfield Management's largest Q2 2022 buy was HilleVax: 2,617,948 shares worth $28.6M.
- Deerfield Management added most to Immunogen Inc in Q2 2022, an estimated $50.2M increase.
- Deerfield Management's biggest Q2 2022 reduction was Kura Oncology, cutting an estimated $25.7M.
- Deerfield Management fully exited Mirati Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $22.2M.
- Deerfield Management's ten largest holdings make up 38% of its $4.85B portfolio in Q2 2022.
- Deerfield Management opened 14 new positions and closed 14 in Q2 2022.
- Deerfield Management's portfolio value rose 8.4% quarter-over-quarter to $4.85B.
Based on Deerfield Management's 13F filing for Q2 2022, filed 15 Aug 2022.